Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

Andrew Tutt, James Carmichael, Michael Friedländer et al.|The Lancet|2010

Cited by 1.6k